ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating…
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge…
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq:…
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting…
49-Year Business Graphics 3 Sold to New Minuteman Press Franchise Owner Tyler Griffith in Coldwater, MI
COLDWATER, Mich., March 04, 2025 (GLOBE NEWSWIRE) -- Graphics 3, a second-generation printing business owned by Iveson family for 49 years, has been sold by retiring owner Mike Iveson to…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact…
Notification of transaction by an Officer of Millicom (Tigo)
Notification of transaction by an Officer of Millicom (Tigo) Luxembourg, March 1, 2025 – Millicom International Cellular S.A. ("Millicom" or the “Company”) announces that, on February 27, 2025, under an…
TransPerfect Acquires Technicolor Games
SAN FRANCISCO and BANGALORE, India, March 01, 2025 (GLOBE NEWSWIRE) -- TransPerfect, the world’s largest provider of language and AI solutions for global business, today announced it has acquired Technicolor…
Merus gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 bekannt und berichtet über die Geschäftsentwicklung
- Phase-III-Zulassungsstudien zu Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung des PD-L1-positiven rezidivierten/metastasierten Kopf-Hals-Plattenepithelkarzinoms (r/m HNSCC) und Petosemtamab als Monotherapie in der Zweit-/Drittlinienbehandlung des r/m HNSCC nehmen Patienten auf;…
Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités
- Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1…